安罗替尼治疗EGFR阳性非小细胞肺癌患者的疗效及对CA125、MMP-2水平的影响

doi:10.3969/j.issn.1671-7171.2026.02.011

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1148 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the efficacy of anlotinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) and its effects on the tumor markers cancer antigen 125 (CA125) and matrix metalloproteinase-2 (MMP-2).【Methods】 A total of 87 patients with EGFR-positive NSCLC were enrolled. Among them, 41 patients received anlotinib treatment (the observation group), and 46 patients received conventional treatment (the control group). Clinical efficacy, immune function, adhesion molecules [soluble intercellular adhesion molecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1)], levels of CA125 and MMP-2 before and after treatment, incidence of adverse reactions, and survival outcomes were compared between the two groups.【Results】 The objective response rate (ORR) in the observation group was significantly higher than that in the control group (P<0.05). After treatment, the observation group showed higher level of CD3⁺/CD4⁺ T cells and a higher CD3⁺CD4⁺/CD3⁺CD8⁺ ratio, but a lower CD3⁺/CD8⁺ ratio compared with the control group (P<0.05). Levels of sICAM-1, sVCAM-1, CA125, and MMP-2 in the observation group were significantly lower than those in the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). The 3-month disease-free survival rate in the observation group was significantly higher than that in the control group (P<0.05).【Conclusion】 Anlotinib is safe and effective treatment for patients with EGFR-positive NSCLC. It can improve immune function and reduce tumor marker levels.

Key words： Carcinoma, Non-Small-Cell Lung Antineoplastic Agents ErbB Receptors CA-125 Antigen Matrix Metalloproteinase 2

Received: 17 June 2025

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHOU Lei
	LI Yongwei
	JIANG Xiaojie
	ZHAO Liang

Cite this article:

ZHOU Lei,LI Yongwei,JIANG Xiaojie, et al. Efficacy of Anlotinib in the Treatment of EGFR-Positive Non-Small Cell Lung Cancer and its Effects on CA125 and MMP-2 Levels[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(2): 216-218.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.02.011 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I2/216

[1] 吕青芳,张鹏,李桂香. PD-1单抗联合化疗对非小细胞肺癌患者淋巴细胞亚群的影响及疗效和预后的相关分析[J].中国肿瘤生物治疗杂志,2025,32(1):73-78.
[2] 董小帅,王昊,艾克东. 酪氨酸激酶抑制剂在分子靶向治疗中对耐药非小细胞肺癌患者角蛋白、PAX-8及DNA EGFR基因T790M突变的影响[J].临床和实验医学杂志,2022,21(6):577.
[3] 蔡明云,宋新宇,黄萃园,等. 第三代表皮生长因子酪氨酸激酶抑制剂非靶点依赖性耐药机制的研究进展[J].医学研究与战创伤救治,2025,38(9):992-997.
[4] 檀紫瑞,申青,刘俊英,等. 表皮生长因子受体非热点突变型非小细胞肺癌一线应用表皮生长因子受体酪氨酸激酶抑制剂及化疗的疗效对比研究[J].中国全科医学,2024,27(35):4426-4434.
[5] 孙子慧,高洋,包曼. 安罗替尼联合TP化疗对Ⅳ期非小细胞肺癌患者近期疗效及VEGF/MAPK/NF-κB通路的调节作用[J].河北医药,2025,47(11):1831-1834.
[6] 于晓麟,华海侠,张丹,等. EGFR ctDNA、TMB及CTCs在EGFR/TP53突变非小细胞肺癌中的疗效预测价值[J].分子诊断与治疗杂志,2025,17(9):1756-1759.
[7] 朱怡璇,汪洋,王彤敏. 免疫检查点抑制剂治疗EGFR-TKIs耐药NSCLC的研究进展[J].中国药房,2025,36(2):239-244.
[8] 张洋,王景景,王博,等. EGFR阳性的晚期NSCLC患者应用吉非替尼治疗的效果及安全性[J].国际医药卫生导报,2025,31(11):1905-1910.
[9] 陈然,高翔,徐福东,等. 晚期EGFR阳性NSCLC患者PD-L1表达特点及其与EGFR-TKIs治疗疗效关系的真实世界研究[J].中国肺癌杂志,2023,26(3):217-227.
[10] 李博文,薛剑超,王亚东,等. 抗血管生成药物联合EGFR-TKI治疗EGFR突变晚期非小细胞肺癌的研究进展[J].中国肺癌杂志,2022,25(8):583-592.
[11] 杨光霞,程云涛,刘琳琳,等. 安罗替尼联合厄洛替尼治疗表皮生长因子受体突变阳性晚期非小细胞肺癌患者的临床研究[J].中国临床药理学杂志,2023,39(20):2905-2909.
[12] 曾壹铭,方文峰,张力. EGFR阳性非小细胞肺癌EGFR-TKI耐药后的治疗现状及未来展望[J].肿瘤防治研究,2025,52(6):429-435.
[13] 董晓荣. 吉非替尼联合异基因CD8⁺自然杀伤T细胞治疗晚期或转移性EGFR突变NSCLC的疗效和安全性[J].循证医学,2025,25(1):25-26.
[14] PASSARO A, MOK T, PETERS S, et al. Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations[J].J Thoracic Oncol,2021, 16(5): 764-773.